During National Apprenticeship Week apprentices and participating employers gathered at Oxford BioMedica to discuss how the first of its kind advanced therapies apprenticeship programme is key to meeting the industry demands for advanced therapies.
Dr Ian Campbell, interim Executive Chair, Innovate UK, delivered the keynote speech and highlighted the Government’s commitment to the programme. Other highlights of the day included a Q&A session with current apprentices and the launch of three new programmes in regulatory affairs, senior management and the Scottish modern apprenticeship in life sciences.
Cambridge, United Kingdom – 18 April, 2019 - Congenica, the global diagnostic decision support platform provider, congratulates its co-founder and Scientific Director, Dr Matthew Hurles, FMedSci FRS, who has been elected to Fellowship of the Royal Society, the UK’s most prestigious scientific organisation.
BioDivide has developed a new stem cell technology for horses called StemPlan. The launch of StemPlan will be supported by a series of CPD events to provide veterinarians with the most up-to-date information about equine regenerative medicine.
Coulter Partners was very pleased to partner with OxStem Limited, a leading biotechnology company focussed on regenerative medicine, to secure the appointment of Dr Stuart Collinson as Chairman and Chief Executive Officer.
Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual circumstances of patients.
LifeArc, one of the UK’s leading medical research charities, has signed a deal to license an ion channel drug discovery programme to Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo). Small molecules, optimised as part of the programme, are capable of affecting the sensitivity of neurons, show efficacy in treating pain and will undergo further pre-clinical development.